Nautilus Biotechnology, Inc. reported total operating expenses of $20.0 million for the fourth quarter of 2024, which was roughly equal to the fourth quarter of 2023 and $0.9 million above the third quarter of 2024.
The company announced an expected extension of its cash runway through 2027, providing additional liquidity to support its ongoing development efforts.
A significant strategic adjustment was also announced, with the broadscale proteome analysis platform launch now targeted for late 2026, a delay from the previous late 2025 target. This decision was made to optimize performance and reduce technical risk, aiming for a more significant and faster ramp-up in revenue and instrument adoption upon launch.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.